Natural, synthetic and semisynthetic glycolipid inhibitors of glioma growth

Bibliography

• STURROCK RR: Cell division in the normal central nervous system. Adv. Cell Neurobiol. (1982) 3:3–33.
   Google Scholar
• KORR H: Proliferation and cell cycle parameters of astrocytes. In: Astrocytes. Fedoroff S, Vernadakis A (Eds), Acad. Press, Inc., London (1986) 3:77–127.
   Google Scholar
• NIETO-SAMPEDRO M, SANETO RP DE VELLIS J, COTMAN CW: The control of glial populations in brain: changes in astrocyte mitogenic and morphogenic factors in response to injury. Brain Res. (1985) 343:320–328.
   PubMed Web of Science ®Google Scholar
• NIETO-SAMPEDRO M: Astrocyte mitogen inhibitor related to epidermal growth factor receptor. Science (1988) 240:1784–1786.
   PubMed Web of Science ®Google Scholar
• NIETO-SAMPEDRO M, BRODERICK JT: A soluble brain molecule related to epidermal growth factor receptor is a mitogen inhibitor for astrocytes Neurosci. Res. (1989) 22:28–35.
   Google Scholar
• ABAD-RODRIGUEZ J, VALLEJO-CREMADES M, NIETO-SAMPEDRO M: Control of glial number: purification from mammalian brain extracts of an inhibitor of astrocyte division. Clio (1998) 22:160–171.
   Google Scholar
• ABAD-RODRIGUEZ J, BERNABE M, ROMERO-RAMIREZ L et at Purification and structure of neurostatin, an inhibitor of astrocyte division from mammalian brain. Neurochem. (2000) 74:2547–2556.
   PubMed Web of Science ®Google Scholar
• SANTOS-BENITO FE NIETO-SAMPEDRO M, FERNANDEZ-MAYORALAS A, MARTIN-LOMAS M: Synthesis of oligosaccharide inhibitors of neural cell division. Carbohydrate Res. (1992) 230:185–190.
   PubMed Web of Science ®Google Scholar
• SANTOS-BENITO FF, FERNANDEZ-MAYORALAS A, MARTIN-LOMAS M, NIETO-SAMPEDRO M: Inhibition of proliferation of normal and transformed neural cells by blood group-related oligosaccharides. Expt. Med. (1992) 176:915–918.
   PubMed Web of Science ®Google Scholar
• NIETO-SAMPEDRO M, BAILON C, FERNANDEZ-MAYORALAS A, MARTIN-LOMAS M, MELLSTROM B, NARANJO JR: Experimental brain glioma: growth arrest and destruction by a blood group-related tetrasaccharide. I Neuropathol. Exper. Neurol. (1996) 55:169–177.
   PubMed Web of Science ®Google Scholar
• ZHU D, CAVENEY S, KIDDER GM, NAUS CCG: Transfection of C6 glioma cells with connexin 43 cDNA: analysis of expression, intercellular coupling, and cell proliferation. Proc. Nati Acad. Sci. USA (1991) 88:1883–1887.
   PubMed Web of Science ®Google Scholar
• ZHU D, KIDDER GM, CAVENEY S, NAUS CCG: Growth retardation in glioma cells cocultured with cells overexpressing a gap junction protein. Proc. Natl. Acad. Sci. USA (1992) 89:10218–10221.
   PubMed Web of Science ®Google Scholar
• TROJAN J, JOHNSON TR, RUDIN SD, ILAN J, TYKOCINSKI M, ILAN J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science (1993) 259:94–97.
   PubMedGoogle Scholar
• AGUILERA B, ROMERO-RAMIREZ L, ABAD-RODRIGUEZ J, CORRALES G, NIETO-SAMPEDRO M, FERNANDEZ-MAYORALAS A: Novel disaccharides inhibitors of human glioma cell division. J. Med. Chem. (1998) 41:4599–4606.
   PubMed Web of Science ®Google Scholar
• ABAD-RODRIGUEZ J, NIETO -SAMPEDRO M: Purification from bovine brain of an inhibitor of astrocyte and C6 glioma cell division. Eur: Neurosci. (1993) 6(Suppl.):23.
   Google Scholar
• IGURO TA, WAKISAKA PI, TERASAKI M et al.: Sialylated Lewisx antigen detected in the sera of cancer patients. The Lancet (1984) 2:817–818.
   PubMed Web of Science ®Google Scholar
• FUKUSHIMA K, HIROTO M, TERASAKI PI, WAKISAKA A. Characterization of sialosylated Lewisx as a new tumor-associated antigen. Cancer Res.(1984) 44:5279–5285
   PubMed Web of Science ®Google Scholar
• WALZ G, ARUFFO A, KOLANUS W, BEVILACQUA M, SEED B: Recognition by ELAM-1 of the Sialyl-Lex determinant on myeloid and tumor cells. Science (1990) 250:1132–1135.
   PubMed Web of Science ®Google Scholar
• TIEMEYER M, SWIEDLER SJ, ISHIHARA M et al.: Carbohydrate ligands for endothelial-leukocyte adhesion molecule 1. Proc. Nati Acad. Sci. USA (1991) 88:1138–1142.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-MAYORALAS A, MARTIN-LOMAS M: Synthesis of 3-and 2'-fucosyl-lactose and 3, 2'-difucosyl-lactose from partially benzylated lactose derivatives. Carbohydr: Res. (1986)154: 93–101
   Web of Science ®Google Scholar
• FERNANDEZ-MAYORALAS A, DE LA FIGUERA N, ZURITAM et al: Central neural tumor destruction by controlled release of a synthetic glycoside dispersed in a biodegradable polymeric matrix. Med . Chem (2003) 46:1286–1288.
   Web of Science ®Google Scholar
• ABRAHAM GA, GALLARDO A, SAN ROMAN J, FERNANDEZ -MAYORALAS A, ZURITA M, VAQUERO J: Polymeric matrices based on graft copolymers of PCL onto acrylic backbones for releasing antitumoral drugs. Biomed. Mater. (2003) 64A:683–647.
   Web of Science ®Google Scholar
• HAKOMORI S, ZHANG : Glycosphingolipid antigens and cancer therapy. Chem. Biol. (1997) 4:97–104.
   PubMed Web of Science ®Google Scholar
• BIRKLE S, ZENG G, GAOL, YU RK, AUBRY J: Role of tumor-associated gangliosides in cancer progression. Biochimie (2003) 85(3/4):455–463.
   Google Scholar
• McKALLIP R, LI R, LADISCH S: Tumor gangliosides inhibit the tumor-specific immune response. Immunol. (1999) 163(7):3718–3726.
   Web of Science ®Google Scholar
• FREDMAN P, HEDBERG K, BREZICKA T: Gangliosides as therapeutic targets for cancer. BioDrugs (2003) 17(3):155–167.
   PubMed Web of Science ®Google Scholar
• HAKOMORI S: Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol. (2001) 491:369–402.
   PubMed Web of Science ®Google Scholar
• GUERRERA M, LADISCH S: N-Butyldeoxynojirimycin inhibits murine melanoma cell ganglioside metabolism and delays tumor onset. Cancer Lett. (2003) 201:31–40.
   PubMed Web of Science ®Google Scholar
• WEISS M, HETTMER S, SMITH P, LADISCH S: Inhibition of melanoma tumor growth by a novel inhibitor of glucosylceramide synthase. Cancer Res. (2003) 63:3654–3658.
   PubMed Web of Science ®Google Scholar
• GULBINS E: Regulation of death receptor signaling and apoptosis by ceramide. Pharmac. Res. (2003) 47(5):393–399.
   Google Scholar
• RADIN NS: Killing cancer cells by poly-drug elevation of ceramide levels. A hypothesis whose time has come? Eur: Biochem. (2001) 268(2):193–204.
   Google Scholar
• BLEICHER RJ, CABOT MC: Glucosylceramide synthase and apoptosis. Biochim. Biophys. Acta (2002) 1585:172–178.
   PubMed Web of Science ®Google Scholar
• DWEK RA, BUTTERS TD, PLATT FM, ZITZMANN N:Targeting glycosylation as a therapeutic approach. Nat. Rev Drug Discov (2002) 1:65–75.
   PubMed Web of Science ®Google Scholar
• BROWN JR, FUSTER MM, WHISENANT T, ESKO JD: Expression patterns of a2,3-sialykransferases and a1,3-fucosyltransferases determine the mode of silalyl Lewis x inhibition by disaccharide decoys. Biol. Chem (2003) 278(27):23352–23359.
   Google Scholar
• FUSTER MM, BROWN JR, WANG L, ESKO JD: A disaccharide precursor of sialyl Lewis x inhibits metastatic potential of tumor cells. Cancer Res. (2003) 63:2775–2781.
   PubMed Web of Science ®Google Scholar
• NEWTON HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways. Expert Rev Anti-Cancer The,: (2003) 3(5):595–614.
   Google Scholar
• OLOFSSON B: Rho guanine dissociation inhibitors: pivotal molecules in cellular signalling. Cell. Signal. (1999) 11(8):545–554.
   PubMed Web of Science ®Google Scholar
• MERLO A: Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg. Rev (2003) 26:145–158.
   PubMed Web of Science ®Google Scholar
• Pathology and genetics of tumours of the nervous system (WHO classification of tumours). Kleihues P, Cavenee WK (Eds) International Agency for Research on Cancer, Lyon, France (2000).
   Google Scholar
• MAHER EA, FURNARI FB, BACHOO RM et al.: Malignant glioma: genetics and biology of a grave matter. Genes Dev. (2001) 15:1311–1333.
   PubMed Web of Science ®Google Scholar
• LIBERMANN TA, NUSBAUM HR, RAZON N et al.: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature (1985) 313:144–147.
   PubMed Web of Science ®Google Scholar
• HERMANSON M, FUNA K, HARTMAN M et al: Platelet-derivated growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res. (1992) 52:3213–3219.
   PubMed Web of Science ®Google Scholar
• LAFUENTE JV, ADAN B, ALKIZA K et al.: Expresion of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor-beta (PDGFR-I3) in human gliomas. MM. Neurosci. (1999) 13:177–185.
   PubMed Web of Science ®Google Scholar
• OUMESMAR BN, VIGNAIS L, BARON-VAN EA: Developmental expresión of platelet-derived growth factor a-receptor in neurons and glial cells of the mouse CNS.J Neurosci (1997) 17:125139.
   Web of Science ®Google Scholar
• SCOLDING NJ, RAYNER PJ, COMPSTON DA: Identification of A2B5-positive putative oligodendrocyte progenitor cells and A2B5-positive astrocytes in adult human white matter. Neuroscience (1999) 89:1–4.
   PubMed Web of Science ®Google Scholar
• HOBSON JP, ROSENFELDTH M, BARAK LS et al.: Role of sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell motility. Science (2001) 291: 1800-1803.
   Google Scholar
• MILJAN EA, BREMER EG: Regulation of growth factor receptors by gangliosides. Sci. STKE (2002) 160:RE15.
   Google Scholar
• CICHOWSKI K, JACKS T: NF1 Tumorsuppressor gene function: narrowing the GAP Cell (2001) 104:593–604.
   Google Scholar
• DING H, RONCARI L, SHANON P et al.: Astrocyte-specific expression of activated p21-Ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res. (2001) 61:3826–3836.
   PubMed Web of Science ®Google Scholar
• HOLLAND EC, CELESTINO J, DAI C et al.: Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. (2000) 25:55–57.
   PubMed Web of Science ®Google Scholar
• CAPONIGRO F, CASALE M, BRYCE J:Farnesyl transferase inhibitors in clinical development. Expert Opin. Investig. Drugs (2003) 12(6):943–954.
   PubMed Web of Science ®Google Scholar
• SENGER DL, TUDAN C, GUIOT MC et al.: Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes Cancer Res. (2003) 62(7):2131–2140.
   Google Scholar
• BROOKS WH, ROSZMAN TL, MAHALEY MS et al.: Immunobiology of primary intracranial tumours. II Analysis of limphocyte subpopulations in patients with primary brain tumours. Clin. Exp. Immunol (1977) 29:61–66.
   Google Scholar
• ROSZMAN TL, BROOKS WH, STEEL C et al: Pokeeweed mitogen-induced immunoglobulin secretion by peripheral blood lymphocytes from patients with primary intracranial tumors. Characterization of T helper and B cell function. I Immunol. (1985) 134:1545–1550.
   Google Scholar
• BROOKS WH, NETSKY, MG, NORMANSELL DE et at Depressed cell-mediated immunity in patients with primary intracanial tumors. Characterization of a humoral immunosuppressive factor. J. Exp. Med. (1972) 136:1631–1647.
   PubMed Web of Science ®Google Scholar
• ROSZMAN TL, BROOKS WH: Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin. Exp. Immunol (1980) 39:395–402.
   Google Scholar
• ASHKENAZI E, DEUSTCH M, TIROSH R et al.: A selective impairment of the 11-2 system in lymphocytes of patients with glioblastomas: increased level of soluble IL-2R and reduced protein tyrosine phosphorilation. Neuroinonunomodulation (1997) 4:49–56.
   PubMed Web of Science ®Google Scholar
• ELLIOTT LH, BROOKS WH, ROSZMAN TL: Activation of immunoregulatory lymphocytes obtained from patients with malignant gliomas. Neurosurg. (1987) 67:231–326.
   Web of Science ®Google Scholar
• MORFORD LA, ELLIOTT LH, CARLSON SL et al.: T cell receptor-mediated signalling is defective in T cells obtained from patients with primary intracranial tumors. J. Immunol. (1997) 159:4415–4425.
   PubMed Web of Science ®Google Scholar
• WESHSLER-REYA R, SCOTT MP: The developmental biology of brain tumors. Ann. Rev Neurosci. (2001) 24:385–428.
   PubMed Web of Science ®Google Scholar
• MERLO A: Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg. Rev (2003) 26(3):145–58.
   PubMed Web of Science ®Google Scholar
• MISCHEL PS, CLOUGHESY TF: Targeted molecular therapy of GBM. Brain Pathol (2003) 13(1):52–61.
   PubMed Web of Science ®Google Scholar
• KNOBBE CB, MERLO A, REIFENBERGER G: Protein signaling in gliomas. Neuro-oncology (2002) 4(3):196–211.
   PubMed Web of Science ®Google Scholar
• FIRE A, XU S, MONTGOMERY MK, KOSTAS SA, DRIVER SE: Potent and specific genetic interference by double-stranded RNA in Caenorhadditis elegans. Nature (1998) 391:806–811.
   PubMed Web of Science ®Google Scholar
• COUZIN J: Breakthrough of the year: Small RNAs make big splash. Science (2002) 298:2296–2297.
   PubMed Web of Science ®Google Scholar
• SIPOS EP, BREM H. New delivery systemsfor brain tumor therapy. Neurol. Clin. (1995) 13:813–825.
   PubMed Web of Science ®Google Scholar